Showing posts with label Biotech/GE. Show all posts
Showing posts with label Biotech/GE. Show all posts

Tuesday, April 6, 2010

Myriad Gene case shakes up and shakes down Biotech Industry


First, I would like to thank Matthew Dillon with the Organic Seed Alliance @Seed_Alliance for pulling me from under my rock and informing me about this very important case.

Judge Sweet of the Southern District of New York invalidated seven patents linked to detecting genetic predisposition of breast and ovarian cancers of the Utah-based Myriad Genetics last week after granting plaintiff’s motion for summary judgment. The plaintiffs were many in number, and consisted of various non-profits and individuals who were unable to receive the test that was a result of all the patents. In a lengthy opinion, which can be found here courtesy of Genomics Law Report, the Court effectively reversed the policy of the USPTO that allowed the patenting of isolated DNA after it was purified from the body using common techniques and turned large segments of biotech patents on their collective ear.

The gist of the case was that the subject matter, the DNA sequences that were extracted, was not patentable as it was not different in character from what the DNA sequences do as its normal function, which would be coding or targeting and identifying nucleotide sequences. Although the DNA was purified (manipulated0 and created to be free-standing “isolated DNA” sequence, it was utilized to perform the same function that it would do without manipulation in order to allow researchers to detect potential mutations on the 13th and 17th chromosome that has been linked to predisposition to breast and ovarian cancers (as well as potentially prostate cancer as the opinion briefly states). Judge Sweet closely analogized the current case with Funk Brothers, where researchers patented their creation of a mixture of bacteria that acted together to perform a desired function that they did not do individually. The patent in that case was invalidated as the Court determined that the bacteria were performing the same actions individually that they would have done prior to being manipulated and grouped therefore it was a law of nature and unpatentable.

This is a major step in defining the line while making it somewhat murky to what is patentable subject matter. The Supreme Court has long recognized three subject areas that would not be entitled to patent protection: “the laws of nature, physical phenomena, and abstract ideas . . .”. The court quoting Chakrabarty (The case that allowed the patentability of living things, which in that case were naturally occurring bacteria that were manipulated to perform the new function of breaking down crude oil). It was a general assumption that through the Chakrabarty case that “anything under the sun that is made by man is patentable”, however the Court declared that these aforementioned exceptions were always meant to be taken into account despite that very lofty statement if you were to look at the full quote from the legislative history of the Patent Act of 1952.

The moral of this story, if this decision were to be affirmed at higher levels is that you have to have any DNA sequence you purify perform a different function than to simply code or target and identify other nucleotide sequences. At first supposition, this case does not seem to threaten genetically modified foods and agriculture that attempts to chemically alter the character of certain food and feedstuffs. I am referring to items such as glysophate resistance in various row crops and similar characteristics.

The second portion of the holding is that the act of “analyzing” and “comparing” was not patentable as well, as those were abstract mental process which is a long-held exception for patentable subject matters as well. This also deals with the transformative language concept and has quite a bit to do with how to write patent claims and their interpretation. Although, its an interesting aspect of the opinion and would be relevant for those drafting claims or learning patent law, it does not add much to our discussion here.

As this opinion is only at the district level, its reach is relatively limited as of this moment in time. The Court even states in its discussion of constitutional avoidance (Rule that a Court is rather to handle issues of statute and resolve those issues in an effort to rule on constitutional issues) that if the Federal Circuit would affirm the decision then it would have an effect on the USPTO policy regarding isolated DNA.

However, the more compelling part of this case for the lay observer is the policy driven dicta that arguably could have impacted this decision, despite the Court’s disclaimer that it was not considering it in this opinion. There was the more human side of the argument that this test was $3000, (1/3 less in Canada where the patent is not recognized) and was not covered by many insurers. Additionally, Myriad sent out cease and desist letters to other researchers and practitioners that were possibly infringing upon their patent, which were effective in chilling others from research similar tests or performing tests. Therefore, there was inadequate means in the market to receive a second opinion on the test, as the only options were a few labs that were licensed under Myriad. This line of rationale leads to a subsequent argument stifling of competition and innovation in such an important area as disease prevention.

On the other side of this argument, the companies and industry groups state that the patent protection is one of the only ways to secure capital investment in researching these areas further. This side goes to the argument that the patent protection is the only safeguard to allow an infusion of monies into this scientific field to allow for innovation. The opinion goes further to explain that Merck essentially put out a free audition to scientists to map the human genome and did not take patent protection over findings, as the human genome was seen to be owned by mankind.

Fascinating arguments on both sides, and I’m sure blogger would not appreciate taking up the bandwidth to hash out all the pros and cons of both sides to eventually lead to a decision of I sure as hell don’t know. However, it does bring this argument even further into the public discourse in the age where patentability of life is becoming ever more important as so many drugs are based on the human genome mapped in the early 2000’s and much of our food and fiber is genetically modified. The opinion briefly discussed a law review speaking of “the tragedy of the anticommons”, which postulates the great number of patent rights holders actually hinders innovation as everyone owns a piece that if researched may overlap someone else’s patent, thereby infringing and subjecting that person to litigation and hefty damage awards.

This concept is particularly apt in light of recent DOJ/USDA antitrust discussions, as much of the anti-competive allegations in row crops are directed at improper use of patents, or just the simple fact that the patent is there in the first place. Cases such as these could fuel fire for much of the fringe legislation that wants all plant patents to look similar to PVPA provisions, which may seem more palpable in the near future based on public perception. It becoming that point where the industry, years after the green revolution, will have to look at itself and see if it is doing right by everyone, or acknowledge if there are ways to tweak the system to encourage innovation and allow for increased competition. This blog post from the Chicago Tribune gives a brief rundown of the happenings going on with the USDA/DOJ discussions that have happened thus far and the Pioneer-Dupont/Monsanto legal squabble.

Tuesday, January 19, 2010

Race to the finish line for Monsanto's GE Alfalfa


This past Friday, the U.S. Supreme Court granted the petition of certiorari in order to hear the GE Alfalfa case, Monsanto Co. v. Geertson Seed Farms, No. 09-475, that has been causing quite a stir in the biotech world. This is fortuitous for many involved in biotech crops as a similar decision came out recently regarding Round-up Ready Sugar Beets. The Sugar Beet case had a similar result to alfalfa in that it required an Environmental Impact Statement (EIS) to look at possible consequences on the human environment instead of the less stringent Environmental Assessment (EA) that was performed by the Animal and Plant Health Inspection Service (APHIS). The petitioner's brief is due February 25, 2010 and the Respondent's Brief is due March 25, 2010, while the end of the October 2009 term for the U.S. Supreme Court is over in June 2010. This makes everything sound like it is on the fast track to hearing a decision relatively quickly, at least in terms of typical judicial time continuum.

However, there is a factor that could cause a concern with this case being heard if it is not rectified with an Order to Stay by the Supreme Court. The EIS that was ordered by the U.S. District Court in the N.D. of California has been completed by the USDA and the comment period is scheduled to close on February 16, 2010. The EIS came to a finding of no significant impact (FONSI) on the human environment, and more than likely, after review comments, APHIS will deregulate GE Alfalfa. This process could potentially take anywhere from 2-6 months depending on the amount of comments. I would expect there to be a lot of comments with the longevity and passion surrounding this issue, and the recent nod from the U.S. Supreme Court. This means the decision from USDA could be out sometime this summer. This could potentially cause a problem for Petitioner who wanted to create a precedent regarding deregulation of GE seeds, as the case may be moot by the time of oral argument or decision.

Article III of the U.S. Constitution has a case or controversy requirement that forms part of its standing analysis, (a.k.a. whether or not the person bring the suit is the proper party to bring the suit if one still exists). In order for a case to be heard there must have at least two litigants that have a controversy upon which the Court can issue a ruling. If the Alfalfa is deregulated prior to a ruling, than Monsanto no longer has a controversy as the alfalfa seed would be like it was prior to a suit ever being brought by a plaintiff, therefore creating a situation where the opinion would be an advisory opinion from the Supreme Court as the gravaman of the suit is moot.

This problem could be solved by Monsanto motioning for a stay of administrative procedures and the U.S. Supreme Court granting such a stay. This may have been done, but I have not seen anything evidencing it yet. The other way to have it solved is to have the Supreme Court move at the same speed of the famous Bush v. Gore case, but I would put my money on the former of my suggestions to occur first.

Friday, November 20, 2009

Canadian Inventor Sues State Research Universities

I like to toss "seed lawsuit" in the google search bar on occasion to see what's going on in the world-at-large beyond the comfortable confines of my office here in suburban Memphis, TN. I came across a story that I have posted on the reciprocal situation in the past. This time a Canadian inventor company sued three state universities from infringement. Duh-duh-duh-duuun, the plot has thickened on the agricultural patent landscape, and now no one is safe.

The full story can be found here, but I will give you a summary of the article. A Canadian inventor, Soheil Sharafabadi, claims that the University of Idaho in conjunction with Oregon State University and Washington State University infringed upon his patent to create new varieties of higher-yielding mustard seed. Obviously this is much further back in the litigation food-chain than a brownbagging case, as we have competing researchers claiming a "cheat" much like the ballyhoo of Irish in response to the Thierry Henry hand-ball situation.

Sharafabadi (more fun to spell than you think) claims that the research universities used his 1990 "Psuedoplastic Yellow Mustard Gum" patent in the development of U of I's new mustard seed varieties. Through his July 23, 2009 complaint, he claims that Idagold (developed by U of I) as well as more than two dozen other mustard seed varieties were developed by his patent. According to the article and Sharafabadi, the actual patented process consists of boiling the seeds to extract the "gum" or mucilage, which he claims is preferable and used by the Universities due to the alternative taking more time for extraction. The mucilage promotes water storage and germination that can lead to higher yields.

As a commenter noted on the article that at first blush the reporter makes this sound as if the Universities stole patented seeds and developed new lines, but rather this is purely a process patent infringement issue as noted in the previous paragraph. So, its not quite the "Escape from L.A." post-apocalyptic anarchy I foreshadowed in the beginning, but it is a slight twist of the stories that I have presented before.

This does not seem to be Sharafadi's first bout over his 1990 patent as can be seen on this website that seems to be set up by him himself, where it is claimed that there was some sort of plagiarism at the University of Manitoba by a Ph.D. candidate. The website is slightly disjointed and rather difficult to muddle through, but there is a letter by Sharafabadi explaining the educational deprivation that plagirism will bring upon the Canadian universities. Either way it seems a 1990 invention has brought Mr. Sharafabadi a 20 year plus fight.

Monday, October 26, 2009

Comment Period extended for High-oleic acid soybean

Animal and Plant Health Inspection Service (APHIS) has sent out notice that it is extending the comment period for Pioneer Hi-Bred International's high-oleic acid soybean petition for nonregulated status. The original petition that was posted to go with the initial period was found to be the incorrect petition, so the comment period has been extended to December 28, 2009. The comment period is also extended for the Environmental Assessment (EA) and the Plant Pest Risk Assessment. The Federal Register notice from October 26, 2009 is posted here.

Thursday, October 22, 2009

Mexico Issues First GM Corn Permits


According to a Reuters article from last week, The Mexican Agriculture Ministry will issue two permits to grow experimental plots of GM corn in regions where there are no native corn varieties. This will put the "birthplace" of corn in the hotbed of controversy over GM foods, but many feel it will help with productivity. The article further states that some Northern Mexico farmers were getting in the game early by illegally growing GM corn prior to any government approval of permits. Supposedly, thirty-five businesses have applied for the permits, including Monsanto.

This battle has gone back over the years, as it was always acceptable to consume GM corn in Mexico, but not plant or grow it. It was said that many farmers ignored this and planted the seeds anyway therefore causing an unintended spread of GM corn within Mexican fields. The report that is the centerpiece of this 2004 Washington Post article states that the proliferation of GM corn in Mexico was also contributed to cross-pollination (a.k.a. genetic drift). That about scares the hell out of most, so its understandable way many fears begin to align in these debates. We'll see how this further develops as this process gives us very interesting insight into the development of biotech plan and attitude that swirled by many of us in the US.


Tuesday, September 22, 2009

Consumer Choice sends Monsanto's Roundup Ready Sugar Beets back to the Deregulation Drawing Board

The Northern District of California handed down a ruling in Center for Food Safety v. Vilsack, No. C 08-00484 JSW (N.D. Cal September 21, 2009) that would requires the USDA to perform an Environmental Impact Statement (EIS) as opposed to an Environmental Assessment (EA) in their determination of whether to deregulate Genetically Modified Sugar Beets (known as Event H7-1). The court procedurally granted plaintiffs' motion for summary judgment and denied Defendants' cross-motion for summary judgment in order to line up its decision with the Geertson Seeds decision out of the Ninth Circuit regarding Roundup Ready Alfalfa.

The actual technology would make the sugar beets glysophate tolerant, which is similar to roundup ready alfalfa technology in the Geertson case. APHIS created an EA in response to the application for deregulation and reached a Finding of No Significant Impact (FONSI). The Court reasoned that the decision not to use the hard look of the EIS was arbitrary and capricious as there was evidence acknowledged by the agency, but cursorily tossed aside, that proved to be "significantly effect" the human environment as stated in the the procedural statute the National Environmental Policy Act (NEPA) .

The determination of whether an impact is significant will be determined by the context and intensity or severity, as it is defined by factors in 40 CFR 1508.27. The analysis of these will be reviewed by the judiciary under the APA's arbitrary and capricious standard. As stated, the Court found the Agency's conclusory statements regarding severity to deifferent factors arbitrary and capricious and ruled against it.

The evidence the court pointed to was the difference in opinion regarding length of time sugar beet pollen that can be carried by wind or animals was viable and the distance it could travel. In the related point that the Court considered significant was the socioeconomic effect on organic farmers or simply non-GMO farmers if genetic drift were to occur and consumer choice, if there is a significant limit of non-GMO sugar beets used in the market. Defedants countered that there was no real organic sugar beet market and that they simply do not have to take socioeconomic factors into the analysis of whether to issue an EIS. Obviously, the counter-arguments did not win the day. The Court reasoned that the socioeconomic and consumer choice factors were interrelated, if not a diresult of, the environmental factors that must be considered, and therefore carry as much weight.

Simple to this analysis is that consumer choice will be taken into account in the Ninth Circuit (if not elsewhere based on the focus of natural and organic products), and the skepticim especially abroad of GMO seeds should send a message to just use the EIS and scrap the EA in assessing deregulation possibility as of right now.

Tuesday, September 1, 2009

Has Consumer Fear Truly Halted Genetic Engineering?

A recent article out of the trade journal Nature Biotechnology, according to seedquest, states that the failure of certain genetically engineered traits to make it to market such as nutritional content, ripening control and processing attributes to reach consumers and processors was due to a failure in the European regulatory regime to allow these products to make it through the approval process. It seems that the sell of herbicide resistant and insecticide resistant were much more successful as the regulatory channels allowed these to go through a relatively easy process and were accepted by the end user - the farmer. Without going into the developments of the regulations themselves, I believe there exists a natural inquiry into this tale - why? Some of the summary of the argument presuppose that the problem arises because the latter benefits were researched and developed during the infancy of agricultural biotechnology.

I believe this is attributed to the basic disconnect between consumers and consumers and producers and/or production methods. The perceived end user for an herbicide resistant soybean would be the consumer as they would be given a cheaper price for soy products due to the possibility of increased yield as it knocks out a predator from depleting the volume of soybeans produced on the same amount of acreage. However, on a practical level, it would seem the consumer does not notice the difference in food prices unless there is significant magnitude in the change. Therefore the true sell would be to the producer as he/she would be the one dealing with the pests that the consumer would never even know about unless there is significant change in the price as they are so far removed from the production of the soybean.

The case is not the same for GM nutrition traits as the true customer would be the consumer as it does not seem to solve a problem for the producer. The technical problem being solved would be a nutrition deficiency or a convenience to obtain nutritional benefits from the product. Allan Bennett, a professor at UC-Davis professor, stated "It had been hoped that these products would directly benefit the general public and change the public perception of agricultural biotechnology". This mentality would be the reason there is opposition from the customer, since many may have not seen the problem beforehand or even recognize the nutrition deficiency as an issue, unlike the producers dealing with crop pests. Therefore the groundwork was never done to create "public" acceptance of the GM benefits as there was never a problem or a recognized problem as it wasn't a generally accepted problem.

I would suggest the regulatory regime is merely a reflection of biotechnology market assuming that there product would be accepted without doing the groundwork of showing how the GM nutritional traits would solve a problem or create a convenience for people that should be desired. It would seem that many developers just assume that there is benefits in the development of these traits and the general usefulness of the technology. GM needed a better marketing and advertising campaign showing the benefits and easing fears for these more direct consumer traits from the get-go, which would have taken pressure off of the regulatory regime and allowed quicker approval without as much mainstream skepticism.

Therefore, the I would venture to say that the regulations were not the true cause of halting "direct benefit to consumer" GMs, but the way they were marketed to the public. The fear of the public, caused by a non-recognition of the benefit as opposed to percieved cost, created a stringent beuracracy.

Friday, July 31, 2009

Tobacco may Help Diabetic Patients in the Future


SemBioSys Genetics Inc., out of Canada, was granted U.S. patent number 7,547, 821 entitled"Methods for the Production of Insulin in Plants". A similar patent was granted in Europe last year, and there are patent applications submitted in a multitude of countries worldwide according to the official company press release. The ever-increasing obesity problem that is facing the United States virtually guarantees great success on the patent as plant production is considered the fastest and cheapest methods of reproducing proteins. They will have a lock on the commercialization processes of this plant production method, I bet you wish you would have wanted to know this before its IPO last week.

From the abstract of the Patent "Production in seeds offers flexibility in storage and shipment of insulin as a raw material, and insulin retains its activity upon extraction from stored seed. Further, the amount of biomass subjected to extraction is limited, due to the relatively low water content of plant seeds." The benefits also include the cost factor in production as the scientists do not have to spend tons of money on generating the proteins within labs in small quantities. There is one aspect of the work that seems to worry me based on language in the patent. The claims of the patent seem to use tobacco, as it is typically an easy plant to use due to its regeneration and large pours that let you pop those proteins right out of the leaves in a vacuum chamber. However, it seems that the inventors would prefer to use the Arabidopsis (first plant that had its genome sequenced due to its simplicity), flax plant, or safflower. I am not sure the reason to steer away form tobacco, as it works well in demonstration scale tests, but perhaps its the perception, cost, complexity of the plant, or a host of other factors in which a learned expert in science or business could provide illumination.

This preference for other plants besides the Arabidopsis concerns me, as I believe it will give it a tougher time through the regulatory channels that transgenic crops must go through with APHIS and FDA. No one is much on tobacco, even smoking "unprocessed" tobacco is odious and the demand for consumption of Arabidopsis is virtually non-existent, so there would be no concern of these seeds getting into the food supply as there is no channel for these seeds. However, flax is being used more and more as an alternative to "traditional" foods with its presumed or known health effects, and safflower is used in vegetable oil and salad dressings. I believe this could cause more obstacles than need to be there during the regulatory phase as well as the possibility of public relations problems. This push-back from segments of the public can be seen in the opposition of corn's usage in pharmacropping.

I will continue to follow the progress of this company's patented invention as it continues its clinical trials and comment on the legal steps it will take and possible ramifications of actions taken while attempting to install it into the commercial chain.

I want to comment, and give credit, on where I get my base information to run off with into fanciful flights of legal discovery and opining upon all things seed. Please visit SeedQuest as they provide far more of an overview of the seed industry than my blog ever could, as they should. Another great resource for topic ideas and the most comprehensive blog regarding the extremely broad field of agricultural law is a combined effort of the National Agricultural Law Center and the American Agricultural Law Center, which can be found here.

-Craig

Thursday, May 21, 2009

Deregulation of Genetically Engineered Plants by APHIS

The Animal Plant Health Inspection Service (APHIS) regulates genetically engineered (GE) products and/or organisms along with the Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) depending on application or use. APHIS’ Biotechnology Regulatory Service (BRS) handles much of the actual permitting and notifying for transportation and interstate commerce of the GE products. Enough acronyms for now, essentially this post will show you how to petition for deregulation of a GE product or organism and what should go into the petition. As of the current date, APHIS has deregulated 75 GE products according to a press release deregulating GE cotton, found at http://www.aphis.usda.gov/newsroom/content/2009/05/cottonge.shtml .

So you find yourself having to fill out permits or notifying APHIS ever time you need to transfer your GE article even though you know its not introducing any plant pests or new plant pests that other organisms already bring into the environment. Well, there is two ways to be determined deregulated for purposes of permitting and/or notification procedures: submitting a new petition or submitting an extension to determine nonreglation base don an antecedent organism.

Submitting a Petition – The Long Haul

We will look at the first method of petitioning first as it will be more applicable for more novel scientific endeavors. The regulations located at 7 CFR 340.6 lay out the steps that need to be taken to petition the Administrator of APHIS for deregulation of a genetically engineered article. APHIS requires the petition to conform to the following format:

Petition for Determination of Nonregulated Status

    The undersigned submits this petition under 7 CFR 340.6 to request that the Administrator, make a determination that the article should not be regulated under 7 CFR part 340.

(Signature)_______________________________________________________

A. Statement of Grounds

    A person must present a full statement explaining the factual grounds why the organism should not be regulated under 7 CFR part 340. The petitioner shall include copies of scientific literature, copies of unpublished studies, when available, and data from tests performed upon which to base a determination. The petition shall include all information set forth in paragraph (c) of 7 CFR 340.6. If there are portions of the petition deemed to contain trade secret or confidential business information (CBI), each page of the petition containing such information should be marked ``CBI Copy''. In addition, those portions of the petition which are deemed ``CBI'' shall be so designated. The second copy shall have all such CBI deleted and shall have marked on each page where the CBI was deleted: ``CBI Deleted.'' If a petition does not contain CBI, the first page of both copies shall be marked: ``No CBI.''

    A person shall also include information known to the petitioner which would be unfavorable to a petition. If a person is not aware of any unfavorable information, the petition should state, ``Unfavorable information: NONE.''

B. Certification

    The undersigned certifies, that to the best knowledge and belief of the undersigned, this petition includes all information and views on which to base a determination, and that it includes relevant data and information known to the petitioner, which are unfavorable to the petition.

(Signature)_______________________________________________________

(Name of Petitioner)_______________________________________________

(Mailing Address)_________________________________________________

(Telephone Number)_______________________________________________

As stated in Section A of the Petition there is required data that must be submitted in the petition. You must:

(1)  Submit a biological description of the unmodified recipient plant and information to identify narrowest taxonomic group of the recipient plant. This is the host plant as in the case of the deregulated cotton, it would be the cotton and the information concerning its narrowest taxonomic identifier;

(2)  Provide relevant experimental data and publications that will give an overview of the GE article, including published and unpublished studies ad tests;

(3)  Describe in detail the “ingredients” of the transformation of the unmodified organism into the regulated GE article including, the differences in genotype, any scientific or common name, as well as locality of the collection, development and production of the: donor organism, vector or vector agent, the inserted genetic material, and the regulated article. Be specific and transparent in these descriptions and remember to label “CBI” if you do not want your trade secrets in the public domain;

(4)  Describe in detail the phenotype of the regulated article, while paying attention to the known and potential differences with the unmodified organism that would show that the GE article poses no greater plant risk than the unmodified organism. You should discuss plant pest risk characteristics, disease and pest susceptibilities, expression of the gene product, new enzymes, changes to the plant metabolism, weediness of the GE article and its possible effect on other plants, transfer of genetic information, environmental effects, and other relevant information that stays within the scope of the showing that the GE article poses no greater risk than the unmodified organism; and

(5)  Provide Field Test Trial reports done under a permit or notification procedure that were done prior to the petition for nonregulated status or a submission for determination of nonregulated status based on an antecedent organism, which is a reference point organism that has already been determined nonregulated.

Filing and Administrative Steps

The Petition is then submitted with a copy to the Administrator at the address specified in the regulation, where it is stamped filed and assigned a petition number that will be used for all business related to the petition. After the filing, APHIS will publish a notice in the Federal Register.

The notice will specify a comments period for 60 days, where the agency will accept comments from any interested person and will utilize them to make a determination. The determination by APHIS will be made 180 days from the “receipt of the completed petition,” and it will either approve in whole or part or simply deny the petition. The petition will then be placed in the public petition file where it can be viewed.

Any person denied may file an appeal within 10 days of receipt of the written denial stating the facts and reasons for the appeal, including any after acquired information that could lead to an approval. This appeal is more or a re-petition as it goes back to the Administrator.

Requesting an Extension – The Express Lane

The second and more streamlined version for deregulation is employed if there is already precedent for deregulation of a similar article. You would request an extension of deregulation determination of an antecedent organism in order to cover your GE article and provide information showing the similarities based on similar criteria as set forth above in the petitioning section. However, unlike the petition there are no mandatory submissions.

APHIS will make a preliminary announcement in the Federal Register of an extension of the determination of nonregulated status 30 days before it is to become final and effective. The 30 days provides a cooling off period to allow other information to surface that may result in a denial of the extension.

If your request is denied, you can submit a modified request based on the rationale for the denial that will be received in the written denial or you can venture down the longer and more arduous process of filing a petition.

Afterthoughts

Although this may get you deregulated by APHIS, please remember that there are independent procedures for the EPA and FDA. I will attempt to discuss those in a later post.